Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.66 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2013751 | 0.89 | GRM5 (0.55) | GRM5SOS1FFAR1P2RX7 | |
| SCHEMBL2015726 | 0.88 | GRM5 (0.55) | GRM5SOS1KCNH2FFAR1 | |
| SCHEMBL2008101 | 0.88 | GRM5 (0.65) | GRM5FFAR1 | |
| SCHEMBL2012209 | 0.86 | GRM5 (0.51) | GRM5FFAR1LMNA | |
| SCHEMBL2013745 | 0.86 | GRM5 (0.53) | GRM5SOS1FFAR1LMNA | |
| SCHEMBL2013405 | 0.84 | GRM5 (0.50) | GRM5SOS1KCNH2FFAR1 | |
| SCHEMBL2009110 | 0.82 | GRM5 (0.49) | GRM5KCNH2FFAR1LMNA | |
| SCHEMBL5042306 | 0.82 | GRM5 (0.60) | GRM5KCNH2FFAR1 | |
| SCHEMBL2013082 | 0.82 | GRM5 (0.54) | GRM5FFAR1 | |
| SCHEMBL4630148 | 0.80 | GRM5 (1.00) | GRM5KCNH2FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964620-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-06-21 | — | — | US | disclosed |
| EP-1831193-B1 | IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-20090018171-A1 | IMIDAZOLE DERIVATIVES | BUETTELMANN BERND | 2009-01-15 | — | — | US | disclosed |
| US-7452909-B2 | Imidazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-20050054686-A1 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054686-A1 | Imidazole derivatives | CHRM2, CHRM1, ARG1 | GRM5 758/4885SOS1 4766/4885KCNH2 418/4885 |
| US-20090018171-A1 | IMIDAZOLE DERIVATIVES | CHRM2, CHRM1, ARG1 | GRM5 758/4885SOS1 4766/4885KCNH2 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.